Erasca (ERAS) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic focus and leadership

• Mission centers on eradicating RAS-driven cancers by targeting the RAS/MAPK pathway with a modality-agnostic pipeline.

• Expanded Scientific Advisory Board with leading experts in RAS biology and resistance mechanisms.

• Maintains strong financial position with $463 million in cash and extended runway into H2 2027.

Pipeline highlights and innovation

• Three main programs: naporafenib (phase 3), ERAS-0015 (pan-RAS molecular glue), and ERAS-4001 (pan-KRAS inhibitor).

• ERAS-0015 and ERAS-4001 both exhibit high preclinical potency, strong oral bioavailability, and robust IP protection through 2043.

• ERAS-0015 demonstrates up to 13-fold higher potency than competitors in preclinical models and maintains high tumor tissue concentrations.

• ERAS-4001 shows broad activity against KRAS mutations, sparing H and NRAS, and supports combination strategies.

Clinical progress and data

• Naporafenib, a pan-RAF inhibitor, shows strong proof of concept in NRAS mutant melanoma with a 40% response rate and 80% disease control rate in SEACRAFT-1.

• Improved safety profile for naporafenib/trametinib with mandatory rash prophylaxis, reducing grade 3 derm toxicities and increasing dose intensity.

• SEACRAFT-2 phase 3 trial is enrolling well, with stage one data readout expected in H2 2024; dose selection will be based on efficacy and safety.

• IND filings for ERAS-0015 and ERAS-4001 are on track, with phase 1 data readouts anticipated next year.